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Background: High-throughput profiling of human tissues typically yield as results the gene lists comprised of a mix
of relevant molecular entities with multiple false positives that obstruct the translation of such results into
mechanistic hypotheses. From general probabilistic considerations, gene lists distilled for the mechanistically
relevant components can be far more useful for subsequent experimental design or data interpretation.
Results: The input candidate gene lists were processed into different tiers of evidence consistency established by
enrichment analysis across subsets of the same experiments and across different experiments and platforms. The
cut-offs were established empirically through ontological and semantic enrichment; resultant shortened gene list
was re-expanded by Ingenuity Pathway Assistant tool. The resulting sub-networks provided the basis for generating
mechanistic hypotheses that were partially validated by literature search. This approach differs from previous
consistency-based studies in that the cut-off on the Receiver Operating Characteristic of the true-false separation
process is optimized by flexible selection of the consistency building procedure. The gene list distilled by this
analytic technique and its network representation were termed Compact Disease Model (CDM). Here we present the
CDM signature for the study of early-stage Alzheimer’s disease. The integrated analysis of this gene signature allowed
us to identify the protein traffic vesicles as prominent players in the pathogenesis of Alzheimer’s. Considering the
distances and complexity of protein trafficking in neurons, it is plausible that spontaneous protein misfolding along
with a shortage of growth stimulation result in neurodegeneration. Several potentially overlapping scenarios of
early-stage Alzheimer pathogenesis have been discussed, with an emphasis on the protective effects of AT-1 mediated
antihypertensive response on cytoskeleton remodeling, along with neuronal activation of oncogenes, luteinizing
hormone signaling and insulin-related growth regulation, forming a pleiotropic model of its early stages. Alignment
with emerging literature confirmed many predictions derived from early-stage Alzheimer’s disease’ CDM.
Conclusions: A flexible approach for high-throughput data analysis, the Compact Disease Model generation, allows
extraction of meaningful, mechanism-centered gene sets compatible with instant translation of the results into testable
hypotheses.
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In developed economies, the costs of medical services are
constantly rising, stifling the growth and projecting to be-
come unsustainable if the trend remains unchanged [1,2].
Some solutions propose the shift of the focus to early
diagnostics of the diseases with the highest societal im-
pact, to designing the strategies for reliable risk assess-
ment and to tailoring prophylaxis efforts to the highest
risk groups [3]. Another approach seeks to streamline the
process of drug development by focusing the effort on the
most promising targets and pre-clinical drug candidates.
Both solutions may be assisted by the methods of bio- and
chemo-informatics that operate within the realm of sys-
tems biology [4-6].
The most common type of the data analyzed by bioin-
formaticians is a set of differentially expressed genes ob-
tained by microarray or RNAseq. Typical candidate list
derived from these kinds of studies contains hundreds to
thousands differentially expressed genes. However valu-
able, these sets are riddled with false-positives that chan-
ged their expression levels due to compensation for an
overall increase in cellular stress or as a secondary effect
of certain regulatory events, for example, the suppression
of transcription factor’ activity or the shift in histone
modification landscape. In other words, the differential ex-
pression of given gene often is a passive consequence of
stress rather than a critical event directly contributing to
disease pathogenesis.
Obviously, the focus of the research efforts should be
on genes most essential in pathogenesis of given disease.
However, this focusing is not trivial, as every chronic
disease is studied by multiple research groups that cus-
tomarily formulate multiple competing hypotheses [7],
thus, populating the lists of potential candidates with
thousands of entries. For Alzheimer’s disease alone, the
Gene Cards compiled by Weizmann Institute of Science
list 1890 molecules of relevance [8]. With < 25,000 genes
known to comprise a genome, and no more than a third
of them being expressed in a single tissue [9], this num-
ber is indicative that the long gene lists of today reflect
rather poor target prioritization. Thus, there is a need
for highly prioritized shortlists of potential targets dir-
ectly linked to major pathogenic processes. Such lists,
contracted by ontological enrichment, re-expanded by
interaction network and validated by network cluster-
ing and alignment with literature were termed here
Compact Disease Models (CDMs).
The reproducibility of a result in an independent ex-
periment with at least slightly varied technical settings is
the typical verification criterion for any scientific deriv-
ation [10]. In accordance to that, the gene-specific
probes differentially expressed in the same direction in
independently analyzed multiple subsets of the same ex-
perimental dataset and also in different experiments areless likely to report noise. Filtering of biological signals
by consistency of gene-expression changes already dem-
onstrated its value for enrichment analyses of genes
mechanistically important for tumorigenesis [11,12] and
metastasis [13]. As compared to gene lists generated
using t-test, the lists generated using consistency of dif-
ferential expression are target-enriched [4,11-14] and,
thus, are more mechanistically relevant. For example, a
reliable cancer mortality signature was produced by
meta-analysis for the consensus changes observed in a
variety of experiments across a number of model organ-
isms [15]. An enrichment of gene expression signatures
with mechanistically relevant targets was also attempted
for neurodegeneration studies, such as Alzheimer’s and
Parkinson’s diseases [16].
While any enrichment technique is capable of demon-
strating the target enrichment, the utility of this enrichment
is determined by the Receiver Operating Characteristic
(ROC) of the process and the point of ROC cut-off. Import-
antly, non-overlapping components of individual data-
sets may be disease-specific while remaining related to
pathogenic mechanism. Therefore, the requirement of
consistency has to be imposed with minimally stringent
cut-offs [17]. Here we present an approach that pro-
vides an improvement over previously described tech-
niques. In that, we implemented sorting out the gene
lists into the Consistency Tiers, thus, gaining control of
the extent of information loss in the non-overlapping
sub-sets. Each Tier can be assessed further by functional
enrichment and alignment with independent literature
data. The optimal size of the consensus signature could be
selected depending on the nature of the disease [17]. All
together, our process includes a three-step noise filter
comprised of 1) prioritization of candidates by consistency
of reported directional gene expression changes, 2) func-
tional enrichment and 3) co-clustering of candidates in a
network [18].
The resultant Compact Disease Model (CDM) pro-
vides a significant saving of research effort. Assuming
N independent platforms being included in given ana-
lysis and m intersections needed to provide a robust
mechanism-related gene list, the number of potential
contributions becomes:
REC ¼ CNmP mð Þ ð1Þ
where REC – is the recall number (the number of totally
available true positives), CN
m is the number of contribut-
ing platform combinations, P(m) is the number of strong
mechanistic associates extracted per a single platform
combination. In this case, the multi-platform nature of an-
alyzed datasets would compensate for a low ROC curve
area observed due to low recall (yield) component, while
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comparative proteomics and quantitative PCR studies,
massive parallel genome sequencing, promoter methyla-
tion arrays or others. To further improve the recall rate
and polish the mechanistic details, the aggregated gene
lists produced by all platforms combined are subjected to
an interaction network building algorithm, sub-network
identification and detailed assessment of the most relevant
sub-networks by literature review.
Compacting mechanistically relevant genes into dis-
tilled shortlists may have a major impact on the routine
verification of individual mechanistic hypotheses. As-
sume that a hypothesis H assigns correct connectivity
between the functions X, Y, Z, the X being a receptor, Y
being a G-protein and Z being a kinase. Relevance of
the gene list is measured by factor of q, where q is the
decimal fraction of bona-fide mechanistically relevant
genes in the total list. The assignment will receive ex-
perimental verification only if all members X, Y, Z are
bona-fide mechanistically related. For a 3-member se-
quence, the relationship is PEC = q3 which can be gen-
eralized into:
PEC ¼ qn ð2Þ
where PEC (probability of experimental correctness) is
the probability that the mechanistic hypothesis is cor-
rect for a n-member sequence; q is the distillation fac-
tor of the list, n is the number of steps in a sequential
mechanistic hypothesis. Under all other factors and
techniques being equal, the exclusion of false positives
from the gene lists is especially important for the
mechanisms studied to a lesser degree (low g) and for
complex hypotheses (high n).
To test CDM approach, we selected an example of
Alzheimer disease, the most common form of adult-onset
dementia. We were especially interested in addressing the
earliest stages of this disease, when the pathological
changes are still reversible and/or preventable. The par-
ticular focus of our analysis was at previously demon-
strated anti-Alzheimer effects of anti-hypertensive drugs
[19-22]. In our study, an application of CDM resulted in
the distilled, tiered list of Alzheimer’s disease-related genes
integrated into a biological network model. As potential
players in early disease, a group of genes that encode pro-
teins associated with traffic vesicles, oncogenes, G-protein
regulators, gonadotropin hormones and insulin-related
signaling molecules was identified. Insights gained by an
analysis of this CDM may aid in shifting the therapeutic
efforts to the reversible stages of neurodegenerative
disease, when the neuronal damage is mild and self-
perpetuating misfolded protein oligomers do not yet form.Methods
Selection of datasets
Datasets for the study included A) GSE5281 on GPL570
HG-U133 Plus 2 Affymetrix Human Genome U133 Plus
2.0 Array including 71 normal controls and 91 disease
related samples (N = 162); B) GSE15222 on GPL2700
Illumina Sentrix Human Ref-8 Expression Bead Chip, in-
cluding 187 normal controls and 176 disease samples
(N = 363); and C) GSE26927 on GPL6255 Illumina hu-
man Ref-8 v2.0 expression bead chip platform, including
58 normal controls and 60 disease samples (N = 118).
The latter dataset comprises differential expression data
covering several neuropathies: Alzheimer’s disease; Amyo-
trophic lateral sclerosis (ALS); Huntington Disease (HD);
Multiple Sclerosis (MS); Parkinson Disease (PD); and
Schizophrenia (SHIZ) of approximately equal size. The pa-
tient histories and disease severities were extracted from
the information that accompanies the public domain data-
sets at GEO, NCBI at http://www.ncbi.nlm.nih.gov/geo/.
Other datasets covering Alzheimer’s disease and dementia
on GPL96 and GPL90 Affymetrix platforms were explored
but not included due to failure to pass the quality controls,
namely, large number of missing genes, evidence of data
imputation or evidence of weak hybridization/weak signal.
The primary data describing datasets A, B and C are pre-
sented in Additional file 1.
Forming of a distilled gene list (CDM): consistency
profiling step
The dataset GSE5281 comprises several distinct tissue sub-
sets: EC - entorhinal cortex; HIP - hippocampus; MTG -
Medial Temporal Gyrus; PC - Posterior Singulate;
SFG - Superior Frontal Gyrus; VCX - Primary Visual
Cortex, each being comprised of control and Alzheimer’s
disease samples. The expression values were averaged for
each anatomical locus for norm and disease. The averaged
signal intensities were sorted by their magnitude and the
upper 40% of the entries were included in the analysis on
assumption that the expression levels for the remaining
low-intensity signals is unlikely to exceed experimen-
tal noise. The ratios of the averages produce either
up-regulated or down-regulated fold change values.
The primary data were subjected to 2-tail, different
variance hypothesis T-tests between normal control and
disease subsets for each brain tissue type. The p-values of
these T tests were converted into negative logarithms and
the logarithms were averaged across all tissue types. For
GSE5281, these averages formed the Primary Consistency
Scores (PCSs). In addition to differential expression, for
each gene, absolute expression levels were also tracked.
The dataset GSE15222 comprises normal controls sepa-
rated into two subsets, numbers 1–85 and 86–178. The
disease samples were also separated into two subsets,
numbers 1–85 and 86–176. Absolute averaged expression
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separately. Similarly to analysis of previous dataset, the
upper 40% of entries by their expression level intensities
were considered significant and included in the analysis.
The difference in expression between the normal and dis-
ease subsets was assessed by T-tests as described above to
compare each disease subset to each normal subset, four
separate values were produced, and the negative decimal
logarithms of T-test p-values were computed. The average
of 4 negative logarithms formed Primary Consistency
scores for GSE15222.
All gene-specific labels in GSE5281 and GSE15222 were
ranked according to their Primary Consistency scores
(PCSs) and the top 10% were selected. The highest rank-
ing probes in GSE5281 and GSE15222 were assigned to a
Consistency Tier 3, if the functionally related molecules
(members of the same pathway) were also displaying high
PCS. Assignment to Consistency Tier 2 was made in ei-
ther of two situations: (a) two Affymetrix probes repre-
senting the same gene were displaying high rank PCS, and
the direction of differential change was the same for both
probes (all down-regulated or all up-regulated) in the
group; (b) Affymetrix and Illumina probes representing
the same gene were displaying high rank PCS and the dir-
ection of differential change was identical for both plat-
forms. Consistency Tier 1 was assigned if either of three
situations: (a) to the genes that displayed high PCS on
both Affymetrix and Illumina platforms as well as multiple
probes on Affymetrix platform, when the direction of dif-
ferential expression changes was the same for all gene-
specific probes; (b) to the probes that simultaneously qual-
ify for Tier 3 and Tier 2; (c) to the three or more probes
on Affymetrix platform that simultaneously showed high
PCS ranking and the direction of expression changes
was identical for all probes. Tiered consistency scores
for all scored genes are available as the dataset D of the
Additional file 1. The Tier 0 was produced by overlap-
ping the Tier 1 and Tier 2 genes with the highest PCS
ranks of GSE26927, thus, identifying a group of genes
commonly participating in a number of neuropathies in
addition to Alzheimer’s disease.
Forming of a distilled gene list (CDM): ontological
enrichment analysis step
Quantitative ontological analysis was performed using
GO-MINER tool (http://discover.nci.nih.gov/gominer/
index.jsp) using high-throughput online computing
option at http://discover.nci.nih.gov/gominer/htgm.jsp.
This technique measures preferential enrichment of the
differentially expressed gene lists in one or more of
approx. 9300 functional categories, organized in a tiled
partially overlapping manner, with smaller specific cat-
egories merging into greater ones. To compute enrich-
ment in a given category, the genes that are known to berelated are tracked in the differential expressed gene list
and in the total list. The enrichment coefficient can be es-
timated as:
ENR ¼ CG=L½ = TG=T½  ð3Þ
Where: ENR – enrichment coefficient, CG – the num-
ber of genes with detected expression changes in a given
functional category in the experimental gene list L, L –
the number of genes in the experimental gene list, TG –
total number of genes in a given functional category,
T – the total number of genes assessed. Robustness of the
enrichment coefficients is established by permuting the
composition of L and expressed as p-value and False Dis-
covery Rate (FDR). The current implementation of GoMi-
ner uses a one-sided p-value calculated from a Fisher’s
exact test. To get a low p-value, good enrichment and a
fairly large size of category are required. The FDR ap-
proach addresses the multiple comparison problem, and
protects against over-interpreting p-values that do not
have a biological meaning.
The combination of Affymetrix and Illumina probe
populations was used as the “Total file” or T. Since
highly expressed genes are more likely to produce con-
sistent differential expression signatures, the total file
(T) was normalized to ensure equal average expression
level as compared to the gene lists (L) under study, com-
pensating this bias. Specifically, the total list in each case
was ranked by expression levels and the upper rank pop-
ulations of T producing equal averages to the given L
were retained as expression-adjusted total files, and the
rest were discarded from the analysis, effectively de-
creasing the number of genes in T. Tier 0, Tier 1, Tier
1 + Tier 2 and Tier 1 + Tier 2 + Tier 3 gene lists were
used as “Changed file”. An option “All” was elected for
“Data source”. Evidence Code was elected as “All”,
accepting either experimental, curator inferred or com-
puted data of functional involvement. Lookup setting
for gene searching in the GO Consortium database was
accepted as achieved by both cross-referencing and by
use of synonyms. Both p-value of a functional enrich-
ment category and false discovery rate (FDR) were
elected as statistical criteria for including the qualifying
genes in the summary report. The prospective func-
tional enrichment categories were validated by 100
randomization cycles according to GO-MINER proto-
col. The smallest size for a functional enrichment cat-
egory was accepted as 5. The GO-MINER output was
sorted by FDR with the cutoff FDR < 0.2. The functional
categories with the lowest false discovery rates were re-
sorted by enrichment coefficients in the descending
order. The relative functional enrichment coefficients
reflect the extent of association of the differentially
expressed genes with the pathological mechanism that
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The outputs of GO-MINER ontological analysis to the
genes within Consistency Tiers 0–3 are available in the
Additional files 2, 3, 4 and 5 datasets G-J.
The extent of ontological enrichment provides a cut-
off for selection of the Consistency Tier levels to be sub-
mitted to network association step. The Tier 1 provided
a conditionally optimal ROC cut-off due to high onto-
logical enrichment and preserved pathway diversity. The
Tier 1 + 2 + 3 was accepted, but considered less preferen-
tial due to a substantially lower proportion of mechanis-
tically relevant genes based on ontological enrichment
step.Forming of a distilled gene list (CDM): network analysis
step
To organize sets of genes into biological networks,
Ingenuity Pathway Assistant (IPA) tool was utilized
(http://ingenuity.com/). Briefly, the tool places a gene list
in the context of experimental and computed interac-
tions systematized in its database. The functional links
between the members of a gene list under study form a
network with high clustering coefficients for members of
the same biological pathway while clustering coefficients
for random associates are low. Indeed, the members of
the same pathway must be functionally associated with
multiple other members of the same pathway, directly or
via intermediates, thus producing non-random cluster-
ing. The extent of observed clustering is compared with
a random model and the extent of observed clustering is
expressed as a p-value of a network. The p-value matches
a probability that the associations in the network have
emerged randomly. The network is partitioned into sub-
networks based on global optimization of clustering when
a gene under consideration is shifted between the sub-
networks as a test. The formed sub-networks are ranked
based on the score, the latter being the negative decimal
logarithm of sub-network non-randomness p-values.
The sets of sub-networks were built using gene lists
comprising Consistency Tier 1 and a joint list comprised
of all three numbered Tiers (Tier 1+ Tier 2 + Tier 3), the
latter as a benchmark control to illustrate the loss of the
priority rank by the sub-network comprising the genes
relevant to neurological diseases. In each analysis, the
highest ranking sub-networks were selected, merged and
plotted as connectivity graphs. The genes displaying ex-
perimentally observed differential expression were co-
plotted with sets of known network interaction partners.
The possible network hubs were expanded, producing
additional connections to more distant members. The
Additional files 6 and 7 comprise the sub-network com-
positions for the Tier 1 and (Tier 1 + Tier 2 + Tier 3), in-
cluding both experimental and inferred members.Validation of CDM by semantic tag enrichment analysis
The quantitative evaluation of enrichment of the microarray-
derived dataset with literature-derived associations was
applied as a validation criterion. Each gene lists was
converted into Boolean [OR] statement, for example:
[gene name 1] OR [gene name 2] OR …etc. and used as
a search query in Pubmed. The hits produced by
PubMed were defined as Total. Additional delimiting
search queries were imposed: A. [(disease or pathology
or disorder)]; B. [cancer]; C [(disease or pathology or
disorder) and stress; D. [(disease or pathology or dis-
order) and (Alzheimer’s or Alzheimer or neuropathy or
neuropathic or neuro-degeneration or neurodegenera-
tion or neurodegenerative or dementia)]. The numbers
of hits for each delimited strategy were enumerated and
related to the number for the total list based on gene
names only. Variation in the datasets was taken into ac-
count by dividing each consistency tier list into subsets
and repeating the procedure independently for each
subset, pooling the variation and distributing it equally
per each subset (within each consistency tier).
In this technique, both [cancer] and [(disease or path-
ology or disorder)] strings were used as controls ac-
counting for non-specific organism or tissue-level stress
that generally accompanies any severe pathology, while
the string [(disease or pathology or disorder) and stress]
was controlling for explicit gene association with stress
in pathological conditions and the string [(disease or
pathology or disorder) and ([Alzheimer’s] or (Alzheimer
or neuropathy or neuropathic or neuro-degeneration or
neurodegeneration or neurodegenerative or dementia)]
was controlling the expected specific association of the
gene lists and the disease of interest.
Results
Overview of differential expression consistency in
Alzheimer’s disease
Affymetrix GPL570 platform comprises approximately
54000 probes, while Illumina platform comprises ~22000
probesets. Of the ~24000 independent expressed genes
measured by both platforms, 78 sets were satisfying cri-
teria of the Tier 0, 105 sets were satisfying the criteria of
the Tier 1, 85 sets were satisfying the criteria of the Tier 2,
450 sets matched the Tier 3 and 1298 sets were demon-
strating high PCS without being validated by other
consistency criteria. On both platforms, the genes within
the top 40% range by their absolute expression served as
random control. Of the 190 probe-sets in Tier 1+ Tier 2,
the Tier 0 comprised 78, indicating that > 40% of genes
robustly reported as being differentially expressed in
Alzheimer’s disease also produced robust detection in
other neuropathies in agreement with [16]. In all
Consistency Tiers, the fold differences of differential
expression effects were relatively small, rarely exceeding
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regulated and the remaining 85 being down-regulated.
In Tier 2, 12 out of 97 probe-sets were up-regulated,
the remaining 85 being down-regulated. In Tier 3, the
down-regulated pattern was shown by 316 genes and
176 genes were up-regulated. In the high PCS/uncon-
firmed group, 715 genes were down-regulated and 570
were up-regulated. In random control, the ratio of up and
down-regulation signals was close to 1. The extent of rela-
tive down-regulation was strongly correlating with the ex-
tent of differential expression detection consistency. These
numbers show a greater tendency for down-regulation
in Alzheimer’s disease-related genes and support func-
tional significance of the consistency profiled gene lists,
in agreement with degenerative character of the Alzhei-
mer’s process [23].
The absolute expression levels were also positively
correlating with consistency of differential expression
detection. Thus, Tier 0 average signal was ~4300 arbi-
trary units, the remaining (Tier 1+ Tier 2) signals were,
after exclusion of Tier 0, at ~2330 arbitrary units, while
the random control genes were at ~1725 arbitrary units
for the top 40% of ranked intensities and ~730 arbitrary
units for the entire array (see the Dataset C in Additional
file 1). The 3 to 5-fold increase in average absolute expres-
sion in the Consistent gene lists vs. Random Control may
be an artifact: the genes with higher expression levels may
also display higher signal-to-noise ratio at hybridization.
Also, at a higher concentration of transcript the thermo-
dynamic quotient and Gibbs energy of binding increases.
For genes with higher expression levels the relative pro-
portion of binding at non-specific sites is lower. However,
it is also known that mechanistically important targets
tend to be the hubs of the biological network that also
tend to be expressed at higher levels than non-hub entities
[24,25]; this feature of biological networks provides add-
itional robustness [26,27]. However, to account for pos-
sible gene intensity bias, further functional enrichment
analysis was conducted after respective normalization.
Another concern was a possibility of a bias due to de-
creased inherent variation within consistently reporting
gene sets, as could be expected for tightly regulated
pathways. If this is true, the consistency in differential
expression of these genes would reflect not a prevalence
of their biological relevancy, but lower levels of respect-
ive backgrounds. To rule this scenario out, variations
were measured among all Consistency Tiers and were
compared to variations observed in Random Control
genes both globally and in the subsets selected by
matching of their expression intensities. The results are
presented in Figure 1.
This analysis points at higher variation in consistent
differentially expressing datasets. Thus, the biased sce-
nario was ruled out and the consistency of the geneexpression changes, indeed, was found to reflect the dif-
ference between the disease and the norm.
Still, there might be a concern that the differentially
expressed data represent stress responses at both organ-
ism and tissue-specific levels, in other words, the re-
sponses expected to be pertinent to any severe pathology
rather than to reflect a disease-specific mechanism.
Figure 2 shows the extracted Consistency Tiers as ana-
lyzed by the methodology described above. The method
comprises the Boolean presentation of the gene list crossed
with the delimiting statement reflecting either associ-
ation with a non-specific stress or with a specific disease.
The statements like [(disease or disorder or pathology)]
crossed with the corresponding Boolean representations
of the consistency tiers would locate the literature pub-
lications associating the genes of interest with any dis-
ease, non-specific to the study. The query statements
like [cancer] crossed with the corresponding Boolean
representations of the consistency tiers would locate
the literature publications associating the genes of
interest with cancer as another proxy for a non-specific
multiple roles played by many signaling molecules. The
statement relating the gene list of interest to stress-
response comprises the negative control. Thus, relative
enrichment of the disease-specific vs. disease non-
specific PubMed hits for certain levels of consistency
would represent a measure of ensuring the mechanistic
involvement of the genes in the disease-specific patho-
genesis Figure 2 represent Venn-transformed enrich-
ment diagrams for all Consistency Tiers.
Based on the results presented in Figure 2, it is appar-
ent that only the Tier 0 produces a highly enriched dis-
ease associated gene list, the Venn Tier 1–0 is still
significantly more enriched than the Random Control
gene list, while an enrichments in Venn Tiers 2–1 and
3–2 were marginal. In fact, the enrichment for the de-
limiter query [(disease or pathology or disorder) and
(Alzheimer’s or Alzheimer or neuropathy or neurode-
generation)] in the Tier 0 was approximately 10 fold as
compared to the Random Control. The degrees of en-
richment against all non-specific disease-related controls
were similar in each Consistency Tier and remained
within a margin of experiment error. All together, against
the non-delimited gene list’ background and against the
panel of negative controls, the disease-specific genes dem-
onstrate the relative enrichment of ~ 10 in the Tier 0, ~3
in the Tier 1–0, ~1.5-2 in the Tiers 1–2 and 3–2.
In its composition, the Tier 3 roughly corresponds to
the target enrichment achievable in a benchmark (trad-
itional) gene expression analysis based on T-test alone
(Figure 2). Low literature tag enrichment in consistency
Tier 3 and in all tiers below Tier 3 questions the mean-
ingfulness of the data not pre-cleaned by triple filtration
of CDM or similar knowledge-based techniques. The








































Ratios of gene expression variations between samples to the expression level
Figure 1 A. Tier 0 and Tier (1 + 2) genes differentially expressed in Alzheimer’s disease and other neuropathies are compared with
significantly expressed random genes on Illumina platform, dataset C. Tier 0 is produced by an overlap of Tier (1 + 2) in Alzheimer’s disease
panel (Datasets A and B) with the multiple neurodegeneration disease panel (Dataset C). Tier (1 + 2–0) is produced by the balance of Tier (1 + 2)
genes with the subtraction of Tier 0. Random genes ranked by intensity were sampled based on the position in the rank. Expression intensities in
the groups of genes formed as described above were measured and plotted.
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for mechanism-inferring purposes contained within Tier
1 and, in some case, Tier 0.
Functional enrichment analysis
Specific pathological mechanisms manifest by differential
expression of genes that belong to just a few selected path-
ways. The effected functional categories may develop high
and statistically significant enrichment coefficients in the
changed gene list. The higher the extent of enrichment, the
stronger is the link between the disease mechanism and
the functional category of interest, pointing to greater spe-
cificity of the signal. Table 1 below combines expression-
normalized functional enrichment coefficients computed
for Top 20 most enriched ontological categories for gene
lists in the Tiers 0–3.
In general, the enrichment coefficients positively cor-
relate with consistency scores, decreasing in the direc-
tion from Tier 1 (highest consistency) to Tier 3 (lowest
consistency). The trend reversal from Tier 0 to Tier 1
can be explained by significant reduction (by 90%) of the
total gene number in the Tier 0 as a result of expression
normalization. In the Top 20 categories, the enrichmentcoefficients were in the range of 4.5-19, with a tendency
to an upper side of the range. In non-normalized data-
sets, the stringent normalization by absolute expression
masks the extent of functional enrichment as it may
reach the values of ~100 for Tier 0 and ~40 for Tier 1,
thus, being far above the typical values observed in trad-
itional microarray experiments [28]. Thus, much higher
distillation coefficient q of the model (1)-(2) may be
reached. Based on comparison of the functional enrich-
ments in CDM approach and the benchmark exempli-
fied by [28], the increase in network-assisted capability
to infer relevant mechanisms may be quite dramatic and
certainly merits further study.
Based on the Table 1, the function of traffic vesicle forma-
tion dominates in the Tiers 0 and 1 and Venn Tier 1 + 2.
This function includes sub-functions of kinesin binding
(synuclein-α; actin β; actin γ1; kinesin-associated protein 3),
clathrine vesicle formation (synaptotagmin 1; synaptotag-
min 13; synaptic vesicle glycoprotein 2B), calcium release
(calmodulin 2; synuclein-α; thymus cell antigen 1, θ; chole-
cystokinin B receptor; guanine nucleotide binding protein
(G protein), γ 3). Synaptic vesicle development categories
were prominent in the Tier 0, while an axon development
Figure 2 Dependence of the relative enrichment in literature-inferred gene roles as a function of detection consistency. For each gene
list (Tier 0, Tier 0–1, Tier 2–1, Tier 3–2, Random control), the gene symbols were converted into a Boolean representation (simply connected by
the operator [OR]). Each Boolean-converted list was used as a query in Pubmed and the number of hits was detected. The primary query for each
gene list was modified by 4 sub-queries, from left to right: Checkered bars: [gene list] + [(disease or pathology or disorder) and (Alzheimer’s or
Alzheimer or neuropathy or neurodegeneration)]; black bars: [gene list] + [cancer]; striped bars: [gene list] + [(disease or disorder or pathology)]; grey
bars: [gene list] + [(disease or pathology or disorder) and stress]. The modified queries produced the numbers of hits smaller than the number of hits
produced by un-delimited gene list in Boolean form. The ratios of the database responses for the modified vs. unmodified query were plotted for each
group of four bars representing a consistency tier. The relative frequencies (ratios) for the queries [(disease or pathology or disorder) and stress] and
[(disease or pathology or disorder) and (Alzheimer’s or Alzheimer or neuropathy or neurodegeneration)] were multiplied by 10 for convenience of
representation and analysis. The Tiers 0–3 represent the lists of genes obtained as disclosed in the Methods; the Tier 1–0 is the result of subtracting the
Tier 0 list from the Tier 1 list; the Tier 2–1 is the result of subtracting the Tier 1 from the Tier 2 list; the Tier 3–2 is the result of subtracting the Tier 2 from
the Tier 3 list; the Random control set was obtained by randomly selecting the genes among Affymetrix and Illumina total lists and the list is not
expression intensity normalized.
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totagmin 1; synaptotagmin 13; synaptic vesicle glyco-
protein 2B). Vesicle formation–related functionalities
displayed the highest enrichment coefficients among all
consistency tiers and were accompanied by the lowest
p-values and FDRs. Microtubule and cytoskeleton de-
velopment were prominent in the Tier 1 and Venn
Tiers 1 + 2 and 1 + 2 + 3 (tubulin, γ complex associated
protein 3; tubulin, γ complex associated protein 2;
tubulin, β 3 class III; tubulin,β 2C; tubulin β, class I;
tubulin, α1c; tubulin, α1b). A related function of cell mo-
tility was predominately populated by the molecules that
relate to mast cell activation (tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, ζ poly-
peptide; thymus cell antigen 1, θ; synuclein-α). Another
prominent functional category, common to the Tiers 0–3,
was MHC binding, receptor binding, ubiquitin targeting
and other forms of protein binding mediated by
proteasome subunits, cytoskeleton and chaperones
(ubiquitin-conjugating enzyme E2N; p21 protein (Cdc42/
Rac)-activated kinase 1; thymus cell antigen 1, θ; actin β;
actin γ1). Regulation of G-protein signaling was highly
enriched category in the most conserved Venn Tiers 0–2(regulator of G-protein signaling 4; regulator of G-protein
signaling 6; regulator of G-protein signaling 7; synuclein-α,
calmodulin 2; cholecystokinin B receptor; γ-aminobutyric
acid (GABA) B receptor, 2; guanine nucleotide binding
protein (G protein), γ3). Less surprisingly, an importance
of GABA neurotransmission was detected (γ-aminobutyric
acid (GABA) B receptor, 2; γ-aminobutyric acid (GABA) A
receptor, gamma 2), as well as related glutamate
secretion (glutaminase; synaptotagmin 1; synuclein-α),
neurotransmitter binding (cholinergic receptor, muscar-
inic 1; cholecystokinin B receptor; γ-aminobutyric acid
(GABA) A receptor, γ2) and brain morphogenesis
(platelet-activating factor acetylhydrolase 1b, regulatory
subunit 1; McKusick-Kaufman syndrome; presenilin 2)
functionalities. Remarkably, consistent datasets lacked
amyloid β (A4) precursor protein APP. One possible
explanation is that differential expression of APP
monomer is negligible, while its pathological role unfolds
at the level of toxic oligomers [29].
Biological network modeling
The molecules populating Consistency Tier 1 that was op-
timal in terms of balance between functional enrichment
Table 1 Enrichment coefficients for top significance functional categories in different Consistency Tiers
Tier Go category TG CG ENR LOG10 (p) FDR
0 GO:0019894_kinesin_binding 8 4 15 −4.1 0.011
0 GO:0007269_neurotransmitter_secretion 38 7 5.7 −3.8 0.018
0 GO:0030426_growth_cone 30 6 6 −3.5 0.024
0 GO:0008021_synaptic_vesicle 42 7 5 −3.5 0.030
0 GO:0007204_elevation_of_cytosolic_calcium_ion_concentration 20 5 8 −3.5 0.028
0 GO:0051480_cytosolic_calcium_ion_homeostasis 22 5 7 −3.3 0.03
0 GO:0051279_regulation_of_release_of_sequestered_calcium_ion_into_cytosol 6 3 15 −3.2 0.05
0 GO:0030672_synaptic_vesicle_membrane 24 5 6.4 −3.1 0.06
0 GO:0010522_regulation_of_calcium_ion_transport_into_cytosol 7 3 13. −3.0 0.06
0 GO:0048854_brain_morphogenesis 7 3 13 −3.0 0.0
0 GO:0050852_T_cell_receptor_signaling_pathway 15 4 8 −3.0 0.06
0 GO:0051648_vesicle_localization 16 4 8 −2.9 0.06
0 GO:0051209_release_of_sequestered_calcium_ion_into_cytosol 8 3 12 −2.8 0.06
0 GO:0051282_regulation_of_sequestering_of_calcium_ion 8 3 12 −2.8 0.06
0 GO:0051283_negative_regulation_of_sequestering_of_calcium_ion 8 3 12 −2.8 0.06
0 GO:0002429_immune_response-activating_cell_surface_receptor_signaling_pathway 17 4 7 −2.7 0.06
0 GO:0002768_immune_response-regulating_cell_surface_receptor_signaling_pathway 17 4 7 −2.7 0.07
0 GO:0050851_antigen_receptor-mediated_signaling_pathway 17 4 7 −2.7 0.07
0 GO:0007281_germ_cell_development 29 5 5 −2.7 0.07
0 GO:0030594_neurotransmitter_receptor_activity 9 3 10 −2.6 0.08
1 GO:0060198_clathrin_sculpted_vesicle 5 3 19 −3.6 0.03
1 GO:0019894_kinesin_binding 9 5 18 −5.5 0.004
1 GO:0042288_MHC_class_I_protein_binding 6 3 16 −3.3 0.05
1 GO:0042287_MHC_protein_binding 7 3 14 −3.0 0.06
1 GO:0051279_regulation_of_release_of_sequestered_calcium_ion_into_cytosol 7 3 14 −3.0 0.06
1 GO:0005834_heterotrimeric_G-protein_complex 12 5 13 −4.8 0.0049
1 GO:0010524_positive_regulation_of_calcium_ion_transport_into_cytosol 5 2 13 −2.0 0.12
1 GO:0035267_NuA4_histone_acetyltransferase_complex 5 2 13 −2.0 0.12
1 GO:0043113_receptor_clustering 5 2 13 −2.0 0.12
1 GO:0045576_mast_cell_activation 5 2 13 −2.0 0.12
1 GO:0046173_polyol_biosynthetic_process 5 2 13 −2.0 0.12
1 GO:0051322_anaphase 5 2 13 −2.0 0.12
1 GO:0051668_localization_within_membrane 5 2 13 −2.0 0.12
1 GO:0010522_regulation_of_calcium_ion_transport_into_cytosol 8 3 12 −2.8 0.06
1 GO:0031177_phosphopantetheine_binding 8 3 12 −2.8 0.06
1 GO:0008277_regulation_of_G-protein_coupled_receptor_protein_signaling_pathway 12 4 11 −3.5 0.03
1 GO:0008298_intracellular_mRNA_localization 9 3 11 −2.7 0.07
1 GO:0032410_negative_regulation_of_transporter_activity 9 3 11 −2.7 0.07
1 GO:0010676_positive_regulation_of_cellular_carbohydrate_metabolic_process 6 2 11 −1.9 0.14
1 GO:0045298_tubulin_complex 6 2 11 −1.9 0.14
1+ 2 GO:0019894_kinesin_binding 9 6 12 −5.7 0.007
1+ 2 GO:0060198_clathrin_sculpted_vesicle 5 3 11 −2.8 0.06
1+ 2 GO:0008298_intracellular_mRNA_localization 9 5 10 −4.4 0.009
1+ 2 GO:0005871_kinesin_complex 8 4 9 −3.3 0.03
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Table 1 Enrichment coefficients for top significance functional categories in different Consistency Tiers (Continued)
1+ 2 GO:0042288_MHC_class_I_protein_binding 6 3 9 −2.5 0.08
1+ 2 GO:0045298_tubulin_complex 6 3 9 −2.5 0.08
1+ 2 GO:0005834_heterotrimeric_G-protein_complex 12 5 7.5 −3.5 0.02
1+ 2 GO:0005881_cytoplasmic_microtubule 15 5 6 −3.0 0.04
1+ 2 GO:0008088_axon_cargo_transport 15 5 6 −3.0 0.04
1+ 2 GO:0008277_regulation_of_G-protein_coupled_receptor_protein_signaling_pathway 12 4 6 −2.5 0.08
1+ 2 GO:0014047_glutamate_secretion 12 4 6 −2.5 0.08
1+ 2 GO:0032182_small_conjugating_protein_binding 16 5 5.6 −2.9 0.045
1+ 2 GO:0043130_ubiquitin_binding 16 5 5.6 −2.9 0.045
1+ 2 GO:0006458_‘de_novo’_protein_folding 26 8 5.5 −4.3 0.009
1+ 2 GO:0006941_striated_muscle_contraction 13 4 5.5 −2.3 0.09
1+ 2 GO:0072384_organelle_transport_along_microtubule 13 4 5.5 −2.3 0.09
1+ 2 GO:0051084_‘de_novo’_posttranslational_protein_folding 24 7 5 −3.6 0.02
1+ 2 GO:0005876_spindle_microtubule 18 5 5 −2.6 0.07
1+ 2 GO:0005200_structural_constituent_of_cytoskeleton 33 9 5 −4.3 0.01
1+ 2 GO:0010970_microtubule-based_transport 26 7 5 −3.4 0.02
1+ 2+ 3 GO:0033180_proton-transporting_V-type_ATPase__V1_domain 7 6 6 −4.2 0.0018
1+ 2+ 3 GO:0004708_MAP_kinase_kinase_activity 6 5 6 −3.4 0.006
1+ 2+ 3 GO:0042288_MHC_class_I_protein_binding 6 5 6 −3.4 0.006
1+ 2+ 3 GO:0042777_plasma_membrane_ATP_synthesis_coupled_proton_transport 6 5 6 −3.4 0.006
1+ 2+ 3 GO:0030897_HOPS_complex 5 4 5 −2.7 0.025
1+ 2+ 3 GO:0031338_regulation_of_vesicle_fusion 5 4 5 −2.7 0.025
1+ 2+ 3 GO:0035542_regulation_of_SNARE_complex_assembly 5 4 5 −2.7 0.025
1+ 2+ 3 GO:0060198_clathrin_sculpted_vesicle 5 4 5 −2.7 0.025
1+ 2+ 3 GO:0046933_hydrogen_ion_transporting_ATP_synthase_activity__rotational_mechanism 15 11 5 −6.3 0
1+ 2+ 3 GO:0046961_proton-transporting_ATPase_activity__rotational_mechanism 18 13 5 −7.2 0
1+ 2+ 3 GO:0004712_protein_serine_threonine_tyrosine_kinase_activity 7 5 5 −2.9 0.014
1+ 2+ 3 GO:0042287_MHC_protein_binding 7 5 5 −2.9 0.014
1+ 2+ 3 GO:0033178_proton-transporting_two-sector_ATPase_complex__catalytic_domain 17 12 5 −6.5 0
1+ 2+ 3 GO:0019894_kinesin_binding 9 6 4.5 −3.2 0.008
1+ 2+ 3 GO:0010676_positive_regulation_of_cellular_carbohydrate_metabolic_process 6 4 4.5 −2.2 0.059
1+ 2+ 3 GO:0035493_SNARE_complex_assembly 6 4 4.5 −2.3 0.059
1+ 2+ 3 GO:0045261_proton-transporting_ATP_synthase_complex__catalytic_core_F(1) 6 4 4.5 −2.3 0.059
1+ 2+ 3 GO:0045739_positive_regulation_of_DNA_repair 6 4 4.5 −2.3 0.059
1+ 2+ 3 GO:0045913_positive_regulation_of_carbohydrate_metabolic_process 6 4 4.5 −2.3 0.059
1+ 2+ 3 GO:0009135_purine_nucleoside_diphosphate_metabolic_process 8 5 4 −2.6 0.032
TG – total genes in a given functional category within the total list T, CG – changed genes within the list L, ENR – enrichment coefficient, LOG10(p) – logarithm of
p-value of one-sided Fisher’s test of significance of a given ENR at a given group size, FDR – false discovery rate. Venn Tier 1 + 2 is the combination of the Tier 1
and Tier 2, Venn Tier 1+ 2 + 3 is the combination of the Tiers 1, 2 and 3.
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pant entries were analyzed using Ingenuity Pathway As-
sistant (IPA) tool. The first order interactions were
imputed automatically, the partners being the hubs of the
cell signaling pathways in network proximity to the chan-
ged genes. The addition provided by the IPA network isvaluable, since this feature partially compensates for low
recall rate observed when the consistency criteria are ap-
plied. The distinctions between the sub-networks are
algorithm-generated and therefore somewhat artificial.
We retained for further analysis all significant hubs re-
gardless of the sub-network they were assigned to by IPA.
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Figure 3 and the composition of the entire network is pro-
vided in Table 2.
According to the Table 2, the sub-networks 1 and 2
demonstrate significant scores associated with p-value of
10-49 and 10-47, respectively, where the score being the
probability that the genes associated at this extent of
clustering were drawn randomly. Per IPA functional as-
signment, the highest score sub-network 1 corresponds
to neurological diseases and comprises vesicle-formingFigure 3 Biological network-based model of interactions between the
the sub-network 1 of Table 2. Green figures indicate down-regulation, re
sion levels. Rectangular figures indicate receptors, rombi –peptidases, triang
binding only, solid connecting arrow – acts upon, dotted lines indicate ind
both genes in cell lines).components in agreement with GO-MINER analysis,
validating the CDM approach from the point of internal
consistency. As a control, a gene list sampling equal to
Tier 1 in size and selected from the T-test enriched popu-
lation (benchmark method, no CDM processing) was ana-
lyzed. The control list prioritized different sub-networks
and emphasized the pro-inflammatory pathways, but not
the neurological disease-specific sub-network as does
CDM list (data not shown). The same trend persisted
across the levels of detection consistency from T-test onlymost essential Alzheimer’s disease-related genes representing
d figures indicate upregulation, grey figures mean unchanged expres-
les – kinases/phosphatases, circles –other; solid connecting line –
irect functional relationships (such as co-regulation of expression of
Table 2 Composition and scoring of Alzheimer’s disease molecular sub-networks generated by IPA






49 23 Neurological Disease, Reproductive System
Development and Function, Cell Death
2 14-3-3,ACTB,ACTG1,Actin,ACTR1A,aldo,Alpha tubulin,ATP5C1,ATP5G1,
ATP6V1D (includes EG:299159),ATP6V1E1,ATP6V1E2,Beta Tubulin,Cofilin,
Dynein,EIF3K,ELAVL4,F Actin, GAPDH, H + −transporting two-sector ATPase,
Hsp90,NFkB(complex),PFDN5,SMARCC1,SNCA,SORBS1,STMN2,TUBA1B,
TUBA1C,TUBB3,TUBB,TUBB2C,Tubulin,Vacuolar H + ATPase,ZBTB20
47 22 Cellular Assembly and Organization, Cellular
Function and Maintenance, Immunological
Disease
3 26sProteasome,Akt,ATP8A2,BAG6,CD3,COPS4, COX5B (includes
EG:100002384),DNAJB12, DNAJC6,DNAJC8,ERK,GABRG2,Hsp70,HSP,HSPA8,
HSPB3,Ikb,Insulin,Jnk,Laminin,LSM14B,Mapk,NDFIP2,P38MAPK,Pka,PPME1,
PSMD4, PTP4A2,SNRPN,Sos,SYT1 (includes EG:20979), TCR,UBE2N,Ubiquitin,
YWHAZ
31 16 Cellular Compromise, Cell-To-Cell Signaling and
Interaction, Cellular Growth and Proliferation
4 ADORA2A,ATP,ATP6V1H,CACNA1E,CACNA2D3,CACNB2,DYNC1I1,EIF1,EIF5B,




29 17 Hematological System Development and





21 12 Connective Tissue Development and Function,
Tissue Morphology, Genetic Disorder
6 ACACB,ATP5A1,ATP5C1,ATP5D,BBX,BCL2L1,CDC16,CUEDC1,CUL3 (includes
EG:26554), DHX30,E2F4,FAM162A,GSK3A,HINT1,IL4 (includes EG:16189),
KCNAB2,LAMP2,mir-451,NACC1,NFIC,OTUD7B,PEBP1,PRKCQ,PSEN1,RELA,
RTN1 (includes EG:104001),SLC11A2, SMAD3,SYT13,TMEM85,TNFSF10,TPT1
(includes EG:100043703),TTK,TUBA3C/TUBA3D, ZNF83
21 12 Nucleic Acid Metabolism, Small Molecule
Biochemistry, Cellular Compromise
7 FAM63A,NAA38 2 1
8 GNB2L1,SLC9A6 2 1 Cell Cycle, Connective Tissue Development and
Function, Developmental isorder
9 DDX19B,GADD45G,RWDD2B 2 1 Tissue Development, Cell Cycle, DNA
Replication, Recombination, and Repair
Molecules in network comprise both experimentally discovered molecules and known/predicted close interaction partners. The Score is a measure of clustering
coefficient between the sub-network components. Focus Molecules are the differentially expressed gene products with experimental evidence of the linkage to
disease pathogenesis and are denoted by capital letters, while small letters designate inferred interactions.
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http://www.biomedcentral.com/1752-0509/7/121and up to the Tier 3. The sub-network 2 comprises mostly
cytoskeleton and mitochondrial components. The sub-
network 3 displays a score of 31 and comprises other
components such as chaperones, ubiquitin pathway mem-
bers and proteasome subunits. Sub-networks 4–9 were
significant but displayed lower scores.
The abundance of oncogenes in the associated hub
subset was remarkable. To quantify the extent of as-
sociation with oncogenes, the symbol T was defined
as Pubmed response to the gene symbol, assumed to
be proportional to the total number of biological in-
teractions mediated by the gene and its products.
High T numbers correspond to the hubs of biological
network.
To put it in a larger genomic context, a random sam-
ple of 118 gene names was extracted and the T-values
were determined, producing 2 hits with 1000 < T < 5000,
2 hits with 5000 < T < 10000 and 1 hit with T > 10000.
Based on this sampling and the total number of genes ~
20000, an estimate of ~ 500 hubs with T > 5000 wasshown for the human interaction network. In the net-
work sample associated with the Tier 1 consistently
expressed gene list, 36 hubs of the comparable connect-
ivity was present per 96 network associates. This is not a
remarkable finding, considering that Ingenuity databank
is likely biased in favor of hub enrichment. However, the
finding that the ratio of oncogenes to tumor suppressors
is skewed toward oncogenes is counterintuitive for a de-
generative disease.
To assess the background ratio of oncogenes vs. sup-
pressors, several databases were enquired. Search of
OMIM (www.ncbi.nlm.nih.gov/omim) leads to 647 hits
responding to the query [(“oncogene or oncogenes”)],
while 882 hits responded to the queries [(“tumor sup-
pressor” or “tumor suppressors”)]. These numbers cor-
respond to ~7:5 ratio of tumor suppressors to oncogenes
in the global network. Similar search with the databases
“Genes” and “Proteins” at NCBI produced ~1:2 ratios.
An analysis of the database GeneCards at www.gene-
cards.org leads to the ratio ~1:1 for the same queries.
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to oncogenes may be assumed as a random global
control.
This ratio markedly differs from the ratio observed in
our data. Tumor suppressor/oncogene ratio in the hubs
associated with neuropathy network was 2:9 (APC and
TGFB1 as tumor suppressors, ERK1/2, AKT, MYC,
FOS, AP-1, BCL2L1, HSP70, HSP90, RELA being pro-
growth and oncogenic, while the MAPK3, MAPK8 and
MAPK14 were marked as having context dependent
dual functions). Except APC, none of the hits in this T
range was associated with “tumor suppressor” label,
while AKT, MYC, FOS, AP-1, BCL2L1, RELA were de-
noted as “oncogenes”.
We further tested if this oncogene association is lim-
ited to our data or is more general. A PubMed query
[(Alzheimer’s or Alzheimer or neuropathy or neuro-
pathic or neuro-degeneration or neurodegeneration or
neurodegenerative or dementia)] was further delimited by
the keywords [(“oncogene” or “oncogenes”)] as well as
[(“tumor suppressor” or “tumor suppressors”)]. The ratio
of 3.4:1 was observed, while a control query [(disease or
disorder)] produced 1.9:1 ratio. Similar queries [neur-
opathy or neurodegeneration] and [dementia or “cognitive
decline”] produced the ratio 3.5:1 above the random ~2:1,
consistent with our data.
The high-T sub-population of network associates was
segregated from the initial changed gene list (Tiers 0, 1–0,
2–1 combined) and all sub-populations underwent a simi-
lar analysis as above. Specifically, the corresponding gene
lists were converted into Boolean queries and were delim-
ited with “oncogene” and “tumor suppressor” terms. The
Alzheimer’s related genes were compared with a random
gene sample. The random control and the initial (non-
tiered) list of differentially expressed genes demonstrated
comparable oncogene/tumor suppressor hit ratios of 2:1,
while the population of extracted network associates pro-
duced the hit ratio of 5.7:1. For sense of perspective, the
corresponding ratio for oncogene BCL2-centered network
was 4.6:1 and for tumor-suppressor-centered p53-
centered network was 1:2.2. Considering these ratios, the
Alzheimer’s disease network associates were as a group
more oncogenic than the associates of BCL-2, considered
to be a benchmark oncogene and this result is counterin-
tuitive, considering the degenerative character of the
disease.
In another analysis, the control query [disease or
disorder] and [activation or activator] generated ~125000
hits, while the query [disease or disorder] and [deactivate
or deactivator or suppressor or repress or repressor]
generated ~25000 hits. The target query [(Alzheimer’s
or Alzheimer or neuropathy or neuropathic or neuro-
degeneration or neurodegeneration or neurodegenerative
or dementia)] and [activation or activator] produced17500 hits, while the query [(Alzheimer’s or Alzheimer or
neuropathy or neuropathic or neuro-degeneration or
neurodegeneration or neurodegenerative or dementia)]
and [deactivate or deactivator or suppressor or repress
or repressor] produced ~1300 hits. The ratios point to
neuropathies being more preferentially associated with
activation processes (compare 125000:25000 for the
control and 17500:1300 for the neuropathies).
Thus, we conclude that an analysis of entire PubMed
shows that the neuropathy-related information is more
closely and paradoxically associated with oncogenes
and activation than with tumor suppressors and
deactivation, confirming the trend observed in our data.
A study of intersection for Alzheimer’s Disease and
Angiotensin receptor blocker response pathways
The limited number of mechanistically relevant members
comprising CDM list allows aligning with the literature
data covering downstream effects of Angiotensin receptor
AT-1. Both the results in Table 2 of the current study and
the AT-1 literature review indicate AT-1 related genes as
likely to mediate the effect of ARBs (angiotensin receptor
blockers) on Alzheimer’s development.
Literature analysis points to significant interaction of
AT-1 pathway with oncogene activation as well as with
luteinizing hormone and insulin dependent pathways in
neurons [30-35]. The role of oncogene modulation in
response to AT1R blockers is complex, with some onco-
genes being inhibited [30,31], while some being up-
regulated [32]. In the cases when the ARBs exhibit
neuroprotective effects via c-JUN inhibition, levels of
other oncogenes remain as they were and the overall im-
pact of oncogenic activation could still be executed
through collateral routes. An example of such collateral
pathway is a compensatory increase in activity of onco-
genic angiotensin II receptor II (AT-2)/MAS pathway
after the blockade of angiotensin II receptor I (AT-1)
[36]. In mouse model, the alleviation of Alzheimer’s dis-
ease was experimentally achieved by hippocampal deliv-
ery of the oncogenic fibroblast growth factor FGF2 [37].
The predominance of neuroprotective effect in oncogene
stimulation by ARBs is emphasized by ARB induction of
IGF1, a molecule with a powerful anabolic and pro-
survival impact [35]. Thus, the connection between AT1R
inhibition and general activation of neuronal oncogenes is
rather prominent in the body of research literature.
The LH/FSH regulation was previously linked to
Alzheimer-like degeneration in murine models [38], thus,
lending greater significance to stimulation of luteinizing
hormone expression by angiotensin II that was previously
observed in neurons [34].
Another group of entries in the higher score sub-
networks 1 and 2 belongs to cytoskeleton rearrangement
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is the necessary step in vasoconstriction and vasodilation, a
major short term effect of any anti-hypertensive drug.
Angiotensin pathway is certainly involved in the pathways
featured in the sub-networks 1 and 2 [39-41]. According to
our data, the most abundant sub-networks of the Tier 1/
sub-network 1 are the regulators of G-protein signaling and
G-proteins: GNAS, GNB5, GNG3, GPRASP2, RGS4, RGS6,
RGS7. The vascular remodeling and vasodilating role of
GRS2, GRS3, GRS5, GRS18 and GNB3 in regulating of vas-
cular tonicity in the context of Angiotensin receptor (AT-1)
signaling was described previously in [42-46]. Vascular tone
is maintained by the cytoskeleton rearrangement and the
intracellular motility, thus connecting it to the protein mis-
folding and/or defective chaperone complex formation.
To conclude, substantial literature evidence connects
the CDM derived in the current report and organized in
the network of Table 2 with Angiotensin Receptor I
pathway or its blockers, in the neuronal setting.
Discussion
Inferring clinically relevant insights from the complex
picture of the quantitative changes in gene expression
levels remains a major challenge of systems biology. An
interpretation of the disease signature remains the least
standardized part of analytic procedures. In most cases,
this analysis is riddled with subjective inference about
whether given change in expression levels should be
classified as causal, passively associated with observed
phenotype or simply incidental to study design. Recent
introduction of knowledge-based algorithms is expected
to aid in producing reasonable hypotheses linking al-
tered pathways to phenotypic changes. In this study, we
attempted to devise knowledge-based algorithm capable
of generating network clustering-validated, highly priori-
tized shortlists of potential targets pertinent to patho-
genesis, the Compact Disease Models, or CDMs. To
generate CDMs, we assume that molecular targets per-
tinent to pathogenesis of certain chronic disease may be
recognized by their consistent visibility (differential ex-
pression, association of SNPs, functional evidence etc.)
across most of independently designed experiments. In
other words, a molecular target highlighted in a majority
of studies (high-prevalence target) is more likely to be
mechanistically important than the target detected in a
minority of studies (low-prevalence target), although this
relationship is may be not so straightforward [17]. The
genes prioritized by relatively simple approach described
in our study are later validated by assessing the reprodu-
cibility of the findings across other technological plat-
forms. Only the strongest signals prevalent in all sample
subsets (“compartments”) would pass such a rigorous
filter. We believe that cross-validated, highly prevalent
molecules are more likely to reflect more fundamentalaspects of the disease and stand closer to causation. If
the high-prevalence targets also form a highly clustered
network, this association cross-validates substantial role
for each of its constituents in the disease etiology, by
compounding the difference in the probability of being
truly causative between more and less prevalent signals.
In this report, Alzheimer’s Compact Disease Model
(CDM) was built using both Illumina and Affymetrix
platforms through extraction of differential expression
data followed by tiering the gene expression evidence
by its consistency. Both microarray platforms rely on
oligonucleotide multi-probe approach; however, the ex-
perimental workflow, probe length, probe choice and
signal processing statistics between the two platforms
substantially differ [47,48]. In our approach, this inter-
platform discrepancy is expected to serve as a filter that
eliminates the signals that display poor consistency due
to low reproducibility of expression level changes or
due to elevated person-to-person expression variability,
thus, cutting out the probability to detect meaningless
(i.e. false positive) signals.Entropic disease model and pleiotropic role of
angiotensin receptor blockers
Based on the observations of the current report, a pleio-
tropic model of early-stage Alzheimer disease could be
proposed.
From very general considerations, a rigid differenti-
ation program and complex shape of the neuron makes
it an inherently disadvantaged cell type. Thermodynam-
ically, expression of a gene in the nucleus that is
followed by long route of the delivery of resultant pro-
tein to the target site at the synaptic junction either in a
folded or properly pre-folded state is unfavorable due to
high Boltzmann entropy loss associated with long pro-
cesses. In the neurons, the travel distances may reach
0.5 -1 m; the maintenance of properly folded protein re-
quires costly coordination of its intracellular traffic with
the chaperone assembly sites and migration of the
chaperone-protein complex to the destination. The high
Boltzmann entropy loss of the process has to be
matched by a high influx of free energy in the protein
traffic path, derived in sufficient stimulation of anabolic
and trophic pathways. This fundamental understanding
is in agreement with our findings that the pathways
jointly implicated in both blood pressure control and
neurodegeneration are mostly anabolic and pro-survival.
When anabolic pathways become down-regulated in
CNS due to aging, neurotoxicity or mutation, it takes its
toll on energy balance within the cell and increases the
risk of misfolding. Thus, the long-term sustainability of
anabolic processes in the neurons may be favored by regu-
lar anti-hypertensive treatments that assist cell survival.
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organization determines the Boltzmann entropy loss.
Disorganized cytoskeleton has higher initial entropy and
the required intra-neuronal coordination would impose
higher entropy costs. Thus, the intensity of anabolic pro-
cesses is not the only factor determining energy supply for
proper protein folding and trafficking. The luteinizing and
follicle stimulating hormones (LH and FSH) both regulate
menstrual cycle in females and spermatogenesis in males
serving as upstream stimulators of androgen and estrogen
production. Importantly, gonadotropins were found to be
involved in the earliest stages of Alzheimer’s disease and
in memory-related processes in humans and in multiple
murine models [49,50]. Non-pituitary expression of FSH
and its co-localization with FSH receptor and GnRH re-
ceptor in rat cerebellar cortex was shown previously [51].
Brain regions susceptible to degeneration in AD are
enriched in both LH and its receptor; moreover, in animal
models of AD, pharmacologic suppression of LH and
FSH reduced plaque formation [52]. As both the oo-
cytes meiosis that is triggered by LH and the process of
spermatogenesis that is initiated by FSH require exten-
sive cytoskeleton remodeling [53,54], it is tempting to
speculate that the Boltzmann entropy state of neuronal
cytoskeleton may be, in part, dependent on FSH and
LH stimulation, possibly through G-protein activation.
Respectively, G-protein regulators form a tightly con-
nected cluster around FSH and LH nodes (Figure 3).
It is generally accepted that the probability of any
chronic disease of old age increases in parallel with an in-
crease in genomic entropy that degrades the complexity of
epigenetic landscapes [55]. Age-dependent demethylation
of the genome leads to an increase in the transcription of
non-coding RNAs, while CpG-rich 5’ regions of select
genes may become hypermethylated [56]. In case of neu-
rons, the global hypomehylation and site-specific hyper-
methylation was found to be associated with degenerative
and psychotic diseases [57,58]. In agreement with these
observations, our data point to an overall decrease in tran-
script expression levels in the most of the functional
categories showing high enrichment coefficients by GO-
MINER. In some form, the down-regulation bias was
traced among ~200 members of the Tiers 0—2 and ~1300
members of consistency Tier 3 and PCS groups. It is pos-
sible that this phenomenon is reflected by negative down-
stream changes in the stability of RNA transcripts and
proteins, efficiency of translation and posttranslational
modifications and, again, protein folding and trafficking.
An exception to this trend is prominent up-regulation of
NF-kB pathway (Figure 3, NF1C), that is involved in in-
flammation, cellular stress and apoptosis.
Another chromatin remodeling associated pathway is
insulin signaling (Table 2). Importantly, IGF1 pathway is
implicated in both life-span control and antihypertensiveresponse. For example, a protective hormone Klotho, a
competitive antagonist of IGF1 in kidney, is known to
reverse degenerative nephropathies in murine models,
and, as well, shown as downregulated in aging primates
through chromatin methylation [59]. Interestingly, an in-
hibition of angiotensin II signaling by counteracting ex-
pression of IGF-II receptor is also shown to up-regulate
Klotho [60,61]. Taken together, these data suggest a po-
tential of antihypertensive agents to oppose the long-
term age-related chromatin remodeling.
Literature validation of the entropic model built based on
CDM filtered gene list
The principle assumption of our study is that the path-
ways that relevant to the disease mechanism should be
consistently discovered in a number of independent
studies. Many pathways highlighted by our enrichment
strategy were also described as experimental findings
relevant to the context of early stages of Alzheimer’s dis-
ease, or, in general, the process of neurodegeneration.
Extreme functional enrichment for protein traffic vesicle
proteins observed in the CDM dataset points to a sub-
stantial role of this mechanism in the neurodegenera-
tion, and is likely to be an early pathogenetic event.
Some experimental reports confirm impairment of pro-
tein vesicle traffic in early stages of neurodegeneration
[62,63]. The body of literature that discusses protein
traffic vesicles in the context of neurodegeneration is
relatively small and recent, as compared to more com-
mon and more general discussions of cytoskeleton and
heat shock protein involvement in Alzheimer’s disease.
Hence, we may conclude that the proposed CDM building
technique aids the acquisition of relatively novel mechan-
istic insights underrepresented in broader literature.
Another important finding of the report is abundance
of oncogenes in the Alzheimer’s disease interaction net-
work built around the CDM gene list cut-off at a Tier 1
consistency. The independent literature search uncovers
numerous publications describing the connection of on-
cogenes to improper, but possibly compensatory reacti-
vation of cell cycle in terminally differentiated neurons
that eventually leads to a cell death [64-66]. An alterna-
tive hypothesis points to the fact that patients with
Alzheimer's disease have lower risk of incident cancer
than general population [64,67,68]. One explanation to
that paradox is a mitochondrial disfunction that is
both implicated in early stages of Alzheimer’s disease
development and impacted by the oncogene-tumor
suppressor balance [66-68]. The connection between
oncogene activation and bioenergy available to a
neuron appears to be well described in the literature,
in agreement with the conclusions of CDM-based ana-
lysis. The mechanistic support to the bioenergetic view
of oncogene role over improper re-activation of cell
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genuity sub-network 2 (Table 2) comprising mitochondrial
ATP-ase subunits vs. sub-networks 8 and 9, comprising
cell cycle components.
Additionally, the CDM gene list analysis uncovers the
prominent role of follicule-stimulating hormone, luteinizing
hormone and gonadotropin in the development of early
Alzheimer’s. The independent literature search presents
evidence of increased expression of LH in the neurons
vulnerable to Alzheimer’s disease [69]. In aged trans-
genic mice with Alzheimer-type of brain degeneration
(Tg 2576), an ablation of the luteinizing hormone by a
gonadotropin-releasing hormone analogue leuprolide
acetate significantly attenuated cognitive decline and
decreased amyloid-beta deposition as compared to
placebo-treated animals [52]. Hence, the data presented
in [69] and [52] and supported by CDM model indicate
an involvement of FSH/LH pathway in Alzheimer’s.
The gene list distilling steps and its subsequent com-
pacting are crucial to CDM-based hypothesis generation.
If these steps would be omitted, the resultant CDM would
be represented by impractically large gene network, domi-
nated by the non-specific pathways common for many
pathologies. In Alzheimers, non-compacted gene lists are
dominated by stress response and inflammatory path-
ways marked as the highest scoring sub-networks.
Without denying the aggravating role of inflammation
in Alzheimer’s disease, inflammation abating approaches
are unlikely to produce sustainable therapeutic results as
they target relatively late stages of pathogenesis. Import-
antly, the distillation of the gene list into compact model
(CDM) introduces an opportunity to catch a glimpse at
possibly causative mechanistic alternatives that otherwise
would took years to uncover through hypothesis-driven
experimental studies that tend to look after overall plausi-
bility of possible findings at the stage of the study design.
While some models caution us against too stringent cut-
offs for initial CDM composition [17], milder cutoffs that
are combined with a cross-platform analysis appear to be
a promising direction that requires further efforts.
Conclusions
Here we present a novel knowledge-based algorithm that
generates network clustering-validated, highly prioritized
shortlists of potential targets pertinent to pathogenesis, the
Compact Disease Models, or CDMs. This algorithm
allowed us to generate a distilled, tiered list of Alzheimer’s
disease-related genes and to derive a pleiotropic, network-
based model for early stages of this disease. In this model,
the first degree network associates were characterized by
strong predominance of oncogenes. Loss of anabolic stimu-
lation in neurons appears to progress with age due to pro-
moter methylation, until the available free energy in the
terminally differentiated cells would cease to compensateBoltzmann entropy loss that is due to the toll of the folding
and long-distance delivery of the neuronal proteins. The
prophylactic, anti-Alzheimer effect of the ARBs and beta
blockers suggest that they play a role at the inception steps
in the development of degenerative symptoms. Conse-
quently, understanding of the pathways opposed by these
agents has a substantial value since these pathways are
likely to be causative to the degenerative process. Based on
this logic, protein traffic vesicles, oncogenes, gonadotropin
hormones and insulin-related pathway were identified as
potential players in early Alzheimer’s disease. This under-
standing may aid in shifting the therapeutic efforts to
the reversible stages of neurodegenerative disease, when
the neuronal damage is relatively mild and self-
perpetuating misfolded protein oligomers are not yet
formed.
Availability of support data
The data set(s) supporting the results of this article are
included within the article and its Additional file 1.
Additional files
Additional file 1: Datasets A, B and C: (the primary data). Dataset D:
Tiered consistency scores for all scored genes.
Additional file 2: The outputs of GO-MINER ontological analysis of
the genes within Consistency Tier 0.
Additional file 3: The outputs of GO-MINER ontological analysis of
the genes within Consistency Tier 1.
Additional file 4: The outputs of GO-MINER ontological analysis of
the genes within Consistency Tier 2.
Additional file 5: The outputs of GO-MINER ontological analysis of
the genes within Consistency Tier 3.
Additional file 6: The sub-network composition for the Tier 1,
including both experimental and inferred members.
Additional file 7: The sub-network composition for the Tiers 1-3,
including both experimental and inferred members.
Abbreviations
ARBs: Angiotensin receptor blockers; AT-1: AT1R – Angiotensin receptor 1;
CDM: Compact disease models.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Both authors contributed to the study design, interpretation of results and
producing the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors express gratitude to the general support provided by College of
Science, George Mason University and the Human Proteome Project
Program of the Russian Academy of Medical Sciences. Open Access fees for
this publication were covered by GMU' Open Access Publishing Fund.
Author details
1The Center of the Study of Chronic Metabolic Diseases, School of Systems
Biology, College of Science, George Mason University, Fairfax, VA 22030, USA.
2Research Centre for Medical Genetics, RAMS, Moskvorechie 1, Moscow,
Russia.
Mayburd and Baranova BMC Systems Biology 2013, 7:121 Page 17 of 18
http://www.biomedcentral.com/1752-0509/7/121Received: 6 March 2013 Accepted: 28 October 2013
Published: 7 November 2013References
1. Los-Angeles T: Soaring cost of Healthcare Sets a Record. 2010. http://articles.
latimes.com/2010/feb/04/nation/la-na-healthcare4-2010feb04.
2. Huffington Post: A Look at Alzheimer’s Health Cost. 2012. http://www.huffingtonpost.
com/2012/03/08/alzheimers-cost-health-medicare-expensive_n_1328986.html.
3. Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Association of
Hemophilia Clinic Directors of Canada Prophylaxis Study Group, et al:
Tailored prophylaxis in severe hemophilia A: interim results from the
first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
J Thromb Haemost 2006, 4(6):1228–1236.
4. Mayburd AL, Golovchikova I, Mulshine JL: Successful anti-cancer drug tar-
gets able to pass FDA review demonstrate the identifiable signature dis-
tinct from the signatures of random genes and initially proposed
targets. Bioinformatics 2008, 24(3):389–395.
5. Hu J, Hagler A: Chemoinformatics and Drug Discovery. Molecule 2002,
7:566–600.
6. Lim Hwa A: Bioinformatics and Cheminformatics in the Drug Discovery
Cycle. In Lecture Notes in Computer Science 1278, Bioinformatics. Edited by
Ralf H, Thomas L, Markus L, Dietmer S. Berlin: Springer-Verlag; 1997:30–43.
7. Sambamurti K, Jagannatha Rao KS, Pappolla MA: Frontiers in the pathogenesis
of Alzheimer’s disease. Indian J Psychiatry 2009, 51(Suppl 1):S56–S60.
8. GeneCards Database. 2012. http://www.genecards.org/index.php?path=/
Search/keyword/Alzheimer%27s.
9. Ramsköld D, Wang ET, Burge CB, Sandberg R: An abundance of
ubiquitously expressed genes revealed by tissue transcriptome
sequence data. PLoS Comput Biol 2009, 5(12):e1000598.
10. Mason R, Gunst R, Hess J: Statistical Design and Analysis of Experiments: With
Applications to Engineering and Science. Volume 474, Wiley Series in
Probability and Statistics - Applied Probability and Statistics Section Series.
2nd edition. Hoboken, NJ: John Wiley & Sons; 2003:760.
11. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al: Large-scale
meta-analysis of cancer microarray data identifies common transcrip-
tional profiles of neoplastic transformation and progression. Proc Natl
Acad Sci U S A 2004, 101:9309–9314.
12. Xu L, Geman D, Winslow RL: Large-scale integration of cancer microarray
data identifies a robust common cancer signature. BMC Bioinformatics
2007, 8:275.
13. Tsoi LC, Qin T, Slate EH, Zheng WJ: Consistent Differential Expression
Pattern (CDEP) on microarray to identify genes related to metastatic
behavior. BMC Bioinformatics 2011, 2(1):438.
14. Mayburd AL: Expression variation: its relevance to emergence of chronic
disease and to therapy. PLoS One 2009, 4(6):e5921.
15. Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a
death-from-cancer signature predicting therapy failure in patients with
multiple types of cancer. J Clin Invest 2005, 115(6):1503–1521.
16. Liu Y, Koyutürk M, Maxwell S, Zhao Z, Chance MR: Integrative analysis of
common neurodegenerative diseases using gene association, interaction
networks and mRNA expression data. AMIA Summits Transl Sci Proc. 2012,
2012:62–71.
17. Barrenas F, Chavali S, Holme P, Mobini R, Benson M: Network properties of
complex human disease genes identified through genome-wide associ-
ation studies. PLoS One 2009, 4(11):e8090.
18. Ochs MF: Knowledge-based data analysis comes of age. Brief Bioinform
2010, 11(1):30–39.
19. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, et al: Use of angiotensin
receptor blockers and risk of dementia in a predominantly male
population: prospective cohort analysis. BMJ 2010, 340:b5465.
20. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM: Associations of anti-
hypertensive treatments with Alzheimer’s disease, vascular dementia,
and other dementias. Alzheimer’s Dis 2011, 26(4):699–708.
21. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, et al: Does use of
antihypertensive drugs affect the incidence or progression of dementia?
A systematic review. Am J Geriatr Pharmacother 2009, 7(5):250–261.
22. Wagner G, Icks A, Abholz HH, Schröder-Bernhardi D, Rathmann W, et al:
Antihypertensive treatment and risk of dementia: a retrospective
database study. Int J Clin Pharmacol Ther 2012,
50(3):195–201.23. Sun J, Feng X, Liang D, Duan Y, Lei H: Down-regulation of energy
metabolism in Alzheimer’s disease is a protective response of neurons to
the microenvironment. J Alzheimers Dis 2012, 28(2):389–402.
24. Mayburd AL: Expression variation: its relevance to emergence of chronic
disease and to therapy. PLoS One 2009, 4(6):e5921.
25. Kafri R, Dahan O, Levy J, Pilpel Y: Preferential protection of protein
interaction network hubs in yeast: evolved functionality of genetic
redundancy. Proc Natl Acad Sci U S A 2008, 105(4):1243–1248.
26. Kitano H: Biological robustness. Nat Rev Genet 2004, 5(11):826–837.
27. Albert R, DasGupta B, Hegde R, Sivanathan GS, Gitter A, et al: Computationally
efficient measure of topological redundancy of biological and social
networks. Phys Rev E Stat Nonlin Soft Matter Phys 2011, 84(3 Pt 2):036117.
28. Merico D, Isserlin R, Stueker O, Emili A, Bader GD: Enrichment map: a
network-based method for gene-set enrichment visualization and inter-
pretation. PLoS One 2010, 5(11):e13984.
29. Bartl J, Meyer A, Brendler S, Riederer P, Grünblatt E: Different effects of
soluble and aggregated amyloid β(42) on gene/protein expression and
enzyme activity involved in insulin and APP pathways. J Neural Transm
2013, 120(1):113–120.
30. Zhang TL, Fu JL, Geng Z, Yang JJ, Sun XJ: The neuroprotective effect of losartan
through inhibiting AT1/ASK1/MKK4/JNK3 pathway following cerebral I/R in
rat hippocampal CA1 region. CNS Neurosci Ther 2012, 18(12):981–987.
31. Palkovits M, Šebeková K, Klenovics KS, Kebis A, Fazeli G, Bahner U, Heidland
A: Neuronal activation in the central nervous system of rats in the initial
stage of chronic kidney disease-modulatory effects of losartan and mox-
onidine. PLoS One 2013, 8(6):e66543.
32. Hashikawa-Hobara N, Hashikawa N, Inoue Y, Sanda H, Zamami Y, Takatori S,
Kawasaki H: Candesartan cilexetil improves angiotensin II type 2
receptor-mediated neurite outgrowth via the PI3K-Akt pathway in
fructose-induced insulin-resistant rats. Diabetes 2012, 61(4):925–932.
33. Mitra AK, Gao L, Zucker IH: Angiotensin II-induced upregulation of AT(1)
receptor expression: sequential activation of NF-kappaB and Elk-1 in
neurons. Am J Physiol Cell Physiol 2010, 299(3):C561–C569.
34. Moreno AS, Franci CR: Estrogen modulates the action of nitric oxide in
the medial preoptic area on luteinizing hormone and prolactin
secretion. Life Sci 2004, 74(16):2049–2059.
35. Harada N, Shimozawa N, Okajima K: AT(1) receptor blockers increase
insulin-like growth factor-I production by stimulating sensory neurons in
spontaneously hypertensive rats. Transl Res 2009, 154(3):142–152.
36. Miyamoto N, Zhang N, Tanaka R, Liu M, Hattori N, et al: Neuroprotective
role of angiotensin II type 2 receptor after transient focal ischemia in
mice brain. Neurosci Res 2011, 61(3):249–256.
37. Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T: FGF2 gene transfer
restores hippocampal functions in mouse models of Alzheimer’s disease
and has therapeutic implications for neurocognitive disorders. Proc Natl
Acad Sci U S A 2011, 108(49):E1339–E1348.
38. Webber KM, Casadesus G, Bowen RL, Perry G, Smith MA: Evidence for the
role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune
Disord Drug Targets 2007, 7(4):300–303.
39. Stroth U, Meffert S, Gallinat S, Unger T: Angiotensin II and NGF
differentially influence microtubule proteins in PC12W cells: role of the
AT2 receptor. Brain Res Mol Brain Res 1998, 53(1–2):187–195.
40. Laflamme L, Gasparo M, Gallo JM, Payet MD, Gallo-Payet N: Angiotensin II in-
duction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect
counteracted by the AT1 receptors. J Biol Chem 1996,
271(37):22729–22735.
41. Govindarajan G, Eble DM, Lucchesi PA, Samarel AM: Focal adhesion kinase
is involved in angiotensin II-mediated protein synthesis in cultured vas-
cular smooth muscle cells. Circ Res 2000, 87(8):710–716.
42. Hercule HC, Tank J, Plehm R, Wellner M, da Costa Goncalves AC, et al:
Regulator of G protein signalling 2 ameliorates angiotensin II-induced
hypertension in mice. Exp Physiol 2007, 92(6):1014–1022.
43. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, et al:
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient
mice. J Clin Invest 2003, 111(4):445–452.
44. Matsuzaki N, Nishiyama M, Song D, Moroi K, Kimura S: Potent and selective
inhibition of angiotensin AT1 receptor signaling by RGS2: roles of its
N-terminal domain. Cell Signal 2011, 23(6):1041–1049.
45. Fujio Y: RGS2 determines the preventive effects of ARBs against vascular
remodeling: toward personalized medicine of anti-hypertensive therapy
with ARBs. Hypertens Res 2010, 33(12):1221–1222.
Mayburd and Baranova BMC Systems Biology 2013, 7:121 Page 18 of 18
http://www.biomedcentral.com/1752-0509/7/12146. Mitchell A, Rushentsova U, Siffert W, Philipp T, Wenzel RR: The angiotensin
II receptor antagonist valsartan inhibits endothelin 1-induced vasocon-
striction in the skin microcirculation in humans in vivo: influence of the
G-protein beta3 subunit (GNB3) C825T polymorphism. Clin Pharmacol
Ther 2006, 79(3):274–281.
47. Chang JW, Wei NC, Su HJ, Huang JL, Chen TC, et al: Comparison of
genomic signatures of non-small cell lung cancer recurrence between
two microarray platforms. Anticancer Res 2012, 32(4):1259–1265.
48. Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, et
al: Evaluation of high-resolution microarray platforms for genomic profil-
ing of bone tumours. BMC Res Notes 2010, 3:223.
49. Verdile G, Laws SM, Henley D, Ames D, Bush AI, et al: Associations between
gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s
disease. Mol Psychiatry 2012. 10.1038/mp.2012.147.
50. Hyde Z, Flicker L, Almeida OP, McCaul KA, Jamrozik K, et al: Higher
luteinizing hormone is associated with poor memory recall: the health in
men study. J Alzheimers Dis 2010, 19(3):943–951.
51. Chu C, Zhou J, Zhao Y, Liu C, Chang P, et al: Expression of FSH and its co-
localization with FSH receptor and GnRH receptor in rat cerebellar cor-
tex. J Mol Histol 2012, 44(1):19–26.
52. Casadesus G, Atwood CS, Zhu X, Hartzler AW, Webber KM, et al: Evidence
for the role of gonadotropin hormones in the development of
Alzheimer disease. Cell Mol Life Sci 2005, 62(3):293–298.
53. Karlsson AB, Maizels ET, Flynn MP, Jones JC, Shelden EA, et al: Luteinizing
hormone receptor-stimulated progesterone production by preovulatory
granulosa cells requires protein kinase A-dependent activation/dephos-
phorylation of the actin dynamizing protein cofilin. MolEndocrinol 2010,
24(9):1765–1781.
54. Nicholls PK, Harrison CA, Walton KL, McLachlan RI, O’Donnell L, et al:
Hormonal regulation of sertoli cell micro-RNAs at spermiation.
Endocrinology 2011, 152(4):1670–1683.
55. Pantic I, Basta-Jovanovic G, Starcevic V, Paunovic J, Suzic S, et al: Complexity
reduction of chromatin architecture in macula densa cells during mouse
postnatal development. Nephrology (Carlton) 2013, 18(2):117–124.
56. King GD, Rosene DL, Abraham CR: Promoter methylation and age-related
downregulation of Klotho in rhesus monkey. Age (Dordr) 2012,
34(6):1405–1419.
57. Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, et al: Mutations in
DNMT1 cause hereditary sensory neuropathy with dementia and
hearing loss. Nat Genet 2011, 43(6):595–600.
58. Pietrzak M, Rempala G, Nelson PT, Zheng JJ, Hetman M: Epigenetic
silencing of nucleolar rRNA genes in Alzheimer’s disease. PLoS One 2011,
6(7):e22585.
59. Johnson AA, Akman K, Calimport SR, Wuttke D, Stolzing A, et al: The role of
DNA methylation in aging, rejuvenation, and age-related disease.
Rejuvenation Res 2012, 15(5):483–494.
60. Yoon HE, Ghee JY, Piao S, Song JH, Han DH, et al: Angiotensin II blockade
upregulates the expression of Klotho, the anti-ageing gene, in an experi-
mental model of chronic cyclosporine nephropathy. Nephrol Dial
Transplant 2011, 26(3):800–813.
61. Chu CH, Lo JF, Hu WS, Lu RB, Chang MH, et al: Histone acetylation is
essential for ANG-II-induced IGF-IIR gene expression in H9c2 cardiomyo-
blast cells and pathologically hypertensive rat heart. J Cell Physiol 2012,
227(1):259–268.
62. Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-
Vargas D, Moreno-Gonzalez I, De Castro V, Jimenez S, Ruano D, Vizuete M,
Davila JC, Garcia-Verdugo JM, Jimenez AJ, Vitorica J, Gutierrez A: Abnormal
accumulation of autophagic vesicles correlates with axonal and synaptic
pathology in young Alzheimer’s mice hippocampus. Acta Neuropathol
2012, 123(1):53–70.
63. Gunawardena S, Yang G, Goldstein LS: Presenilin controls kinesin-1 and
dynein function during APP-vesicle transport in vivo. Hum Mol Genet
2013, 22(19):3828–3843.
64. Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, Kiel DP, Lu KP,
Seshadri S, Wolf PA: Inverse association between cancer and
Alzheimer’s disease: results from the Framingham Heart Study.
BMJ 2012, 344:e1442.
65. Keeney JT, Swomley AM, Harris JL, Fiorini A, Mitov MI, Perluigi M, Sultana R,
Butterfield DA: Cell cycle proteins in brain in mild cognitive impairment:
insights into progression to Alzheimer disease. Neurotoxicity Research
2012, 22(3):220–230.66. Sieradzki A, Yendluri BB, Palacios HH, Parvathaneni K, Reddy VP, Obrenovich ME,
Gąsiorowski K, Leszek J, Aliev G: Implication of Oncogenic Signaling Pathways
as a Treatment Strategy for Neurodegenerative Disorders-Contemporary
Approaches. CNS Neurol Disord Drug Targets 2011, 10(2):175–183.
67. Demetrius LA, Simon DK: The inverse association of cancer and
Alzheimer’s: a bioenergetic mechanism. J R Soc Interface 2013,
10(82):20130006.
68. Eckert GP, Renner K, Eckert SH, Eckmann J, Hagl S, Abdel-Kader RM, Kurz C,
Leuner K, Muller WE: Mitochondrial dysfunction–a pharmacological target
in Alzheimer’s disease. Mol Neurobiol 2012, 46(1):136–150.
69. Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G,
Atwood CS: Elevated luteinizing hormone expression colocalizes with
neurons vulnerable to Alzheimer’s disease pathology. J Neurosci Res 2002,
70:514–518.
doi:10.1186/1752-0509-7-121
Cite this article as: Mayburd and Baranova: Knowledge-based compact
disease models identify new molecular players contributing to early-
stage Alzheimer’s disease. BMC Systems Biology 2013 7:121.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
